Jon Byrne and Madalina Garbi explore the latest guidelines and current practice around transcatheter valve interventions (including aortic valve implantation (TAVI), mitral regurgitation management and tricuspid valve repair) – which patients are suitable for these interventions, and how do they compare to traditional surgical approaches?

Professor Paul Kalra summarises key findings presented at the 2024 Heart Failure Association ESC meeting in Lisbon. He discusses the new data on hypertrophic cardiomyopathy, heart failure with reduced ejection fraction, and challenges in diagnosis and treatment optimisation. He also explores the early benefits of sodium-glucose co-transporter 2 inhibitors and evidence-based treatments for heart failure with preserved ejection fraction.